Product Synopsis
Pharmaceutical Business Confidence
Report Q1 2014 is a new report by Kable that analyzes pharmaceutical industry
executives views on the global economy, expectations on customer confidence,
supplier prices, key business concerns, and how executives future investments
are set to change in Q1 2014. This report also gives you access to regional
analysis of industry outlook, industry and company growth prospects, future
opportunities, staff hiring, and sales performance. Apart from providing access
to the opinions and strategies of global pharmaceutical industry executives, it
also examines their actions surrounding business priorities, threats and
opportunities, and future investment areas over the next six months. Moreover,
this report provides a comparative analysis of survey results with Q4 2013
wherever applicable.
Introduction and Landscape
* Why was the report written?
- This report is the result of an
extensive survey drawn from Kables exclusive panel of leading global
pharmaceutical industry executives. The report analyzes current economic
conditions prevailing across the globe and their impact on the pharmaceutical
industry, and forecasts company and industry growth prospects over the next six
months. Furthermore, it provides information about the impact of customer
confidence, supplier prices, and staff headcount likely to affect the
investment decisions of the industry over the next six months. Additionally,
this report tracks the change in executives perceptions during the last three
months, by providing a comparative analysis of survey results with the previous
quarter.
* What is the current market
landscape and what is changing?
- Overall, 74% and 60% of global
pharmaceutical industry executives are optimistic about the future growth
prospects of both their company and the industry, respectively, over the next
six months. Optimism towards company and industry growth prospects has improved
by eight and ten percentage points, respectively, in Q1 2014, compared to Q4
2013 results.
* What are the key drivers behind
recent market changes?
- Optimism towards industry and
company growth is driven by the improving global economic conditions,
investments in emerging markets, and the introduction of new products in the
market.
* What makes this report unique and
essential to read?
- Pharmaceutical Business Confidence
Report Q1 2014 is a new report by Kable that analyzes the industry sentiments
globally on the latest economic and customer issues and their impact upon
investment decisions and growth prospects within the pharmaceutical industry.
This report also examines the executive opinion about the current and future
state of the economy and its retrospective effect on the industry. Furthermore,
it analyzes the likely effect of supplier price changes, sales performance, and
staff headcount within the industry over the next six months. In addition, it
provides an overview of the key priorities, threats, and opportunities for the
global pharmaceutical industry over the next six months. Furthermore, it also
tracks the change in industry executives thought process, by providing a
comparative analysis of survey results with Q4 2013, wherever applicable.
Key Features and Benefits
* Project industry trends and
industry growth expectations in the next six months, and understand business
confidence to make informed business decisions.
* The report drives revenues by
understanding future product investment areas and key growth regions.
* Readers will be provided with a
clear uncovering of key challenges and opportunities, and identify the key
priorities likely to affect growth prospects of the industry.
* The report clearly forecasts the
change in supplier prices for various products, which are likely to influence
the industrys growth prospects over the next six months.
* Identifies the major changes in
customer confidence levels in the pharmaceutical industry over the next six
months.
Key Market Issues
* According to pharmaceutical
industry respondents, the present economic conditions in Africa and the Middle
East are deemed to be unfavourable. In the Q4 2013 survey, similar opinions
were recorded.
* New government
proposals/legislation, competition from new entrants, state of global economy,
and performance of the Eurozone are the key concerns among global
pharmaceutical industry executives.
* Survey respondents forecast that
supplier prices for raw materials will increase at an average of 4.1%, with
those from Asia-Pacific expecting the biggest rise.
* In total, 52% of global
pharmaceutical industry executives anticipate either no change or a negative
change in customer confidence over the industry, in the next six months.
* Industry executives exhibit high
levels of optimism towards company growth prospects compared to industry growth
prospects, in the next six months
Key Highlights
* Of respondents, 66% anticipate a
positive change in the global economic outlook over the next six months. In
comparison to previous quarter, the percentage of respondents who expect a
positive change has increased by eighteen percentage points.
* Pharmaceutical industry executives
plan to increase investments in the areas of new product development and
marketing in the next six months.
* Executives operating in the Rest
of the World and Asia-pacific anticipate the highest average sales increase of
6.4% and 4.5%, respectively, over the next six months.
* Industry executives operating in
the Rest of the World and Europe anticipate an average increase of 3.2% and
2.2%, respectively, in their current workforce.
* Executives operating across the
globe consider increasing sales, improving operational efficiency, and customer
retention as key priorities over the next six months.
To order this report:
Email: customerservice@researchonglobalmarkets.com
US:
+1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com
RELATED LINK:
RELATED VIDEO:
No comments:
Post a Comment